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Summary
Background Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum 
and fl uoropyrimidines has not shown benefi ts in health-related quality of life (HRQoL). We assessed whether the 
addition of docetaxel to active symptom control alone can improve survival and HRQoL for patients.
Methods For this open-labelled, multicentre trial, we recruited patients aged 18 years or older from 30 UK centres. 
Patients were eligible if they had an advanced, histologically confi rmed adenocarcinoma of the oesophagus, 
oesophagogastric junction, or stomach that had progressed on or within 6 months of treatment with a platinum-
fl uoropyrimidine combination. Patients could have an Eastern Cooperative Oncology Group performance status of 
0–2. We randomly assigned patients using a central, computerised minimisation procedure to receive docetaxel plus 
active symptom control, or active symptom control alone (1:1; stratifi ed by disease status, disease site, duration of 
response to previous chemotherapy, and performance status). Docetaxel was given at a dose of 75 mg/m² by 
intravenous infusion every 3 weeks for up to six cycles. The primary endpoint was overall survival, analysed by 
intention to treat. This is the report of the planned fi nal analysis. This study is an International Standardised 
Randomised Controlled Trial, number ISRCTN13366390.
Findings Between April 21, 2008, and April 26, 2012, we recruited 168 patients, allocating 84 to each treatment group. 
After a median follow-up of 12 months [IQR 10–21]) and 161 (96%) deaths (80 in the docetaxel group, 81 in the active 
symptom control group), median overall survival in the docetaxel group was 5·2 months (95% CI 4·1–5·9) versus 
3·6 months (3·3–4·4) in the active symptom control group (hazard ratio 0·67, 95% CI 0·49–0·92; p=0·01). Docetaxel 
was associated with higher incidence of grade 3–4 neutropenia (12 [15%] patients vs no patients), infection (15 [19%] 
patients vs two [3%] patients), and febrile neutropenia (six [7%] patients vs no patients). Patients receiving docetaxel 
reported less pain (p=0·0008) and less nausea and vomiting (p=0·02) and constipation (p=0·02). Global HRQoL was 
similar between the groups (p=0·53). Disease specifi c HRQoL measures also showed benefi ts for docetaxel in 
reducing dysphagia (p=0·02) and abdominal pain (p=0·01).
Interpretation Our fi ndings suggest that docetaxel can be recommended as an appropriate second-line treatment for 
patients with oesophagogastric adenocarcinoma that is refractory to treatment with platinum and fl uoropyrimidine.
Funding Cancer Research UK.
Introduction
Globally, gastric cancer is the fourth most common type 
of cancer, with 989 000 new cases a year, and oesophageal 
cancer is the seventh, with 482 000 new cases a 
year.1 Patients are most commonly diagnosed with 
locally advanced or metastatic oesophagogastric cancer, 
except for in Asia, where screening programmes for 
gastric cancer are common. For patients with advanced 
or metastatic disease, outcomes are poor: median overall 
survival is 8–12 months with fi rst-line chemotherapy. 
Even after combination treatment including surgery, 
more than half of patients in western populations 
relapse.2 When relapse or progression occurs after fi rst-
line treatment, median overall survival with supportive 
care is only 3–4 months.3 The high global incidence of 
oesophago gastric cancer, the high relapse rate, and the 
short survival after relapse or progression indicate an 
urgent need for eff ective second-line treatment.
When we planned this trial, we knew of no randomised 
data indicating any benefi t to second-line chemotherapy. 
The best evidence consisted of small (fewer than 50 patients) 
phase 2 trials, fi ndings from which had suggested tumour 
responses with diff erent chemo therapy agents including 
irinotecan4 and docetaxel.5 The largest series reported 
154 patients treated with docetaxel 75 mg/m² of body 
surface area every 3 weeks after failure of a platinum and 
fl uoropyrimidine combination, with a response rate of 14% 
and median overall survival of 7·2 months.6 However, 
potential for toxicity from chemo therapy is high in this 
group of patients with a poor prognosis, and there was no 
evidence that chemotherapy improved either survival or 
health-related quality of life (HRQoL).
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We therefore aimed to assess the benefi ts of second-
line docetaxel in patients whose disease had progressed 
within 6 months of previous chemotherapy. In particular, 
we aimed to fi nd out whether any survival benefi t came 
with an improvement in HRQoL.
Methods
Study design and patients
This multicentre, open-label, randomised, controlled 
phase 3 trial was designed by the COUGAR-02 Trial 
Management Group under the auspices of the Upper 
Gastrointestinal Cancer Clinical Studies Group of the 
UK National Cancer Research Institute. We did the study 
in 30 UK sites. Patients at least 18 years old with 
histologically confi rmed adenocarcinoma of the 
oesophagus, oeso phago gastric junction, or stomach were 
eligible for inclusion if they had advanced disease and 
documented disease progression during or within 
6 months of treatment with platinum and fl uoro-
pyrimidine-based treatment (which could have been 
given as adjuvant or neoadjuvant therapy, or for advanced 
disease). Patients with disease-free intervals longer than 
6 months were not eligible because the most common 
UK practice is that patients with a treatment-free interval 
of more than 6 months with chemotherapy would be 
either re-challenged with the original chemotherapy or 
off ered second-line chemo therapy. We felt that it was not 
appropriate to off er these patients active symptom 
control. Further inclusion criteria were an Eastern 
Cooperative Oncology Group (ECOG) performance status 
of 0 (normal) to 2 (symptomatic but in bed or chair less 
than 50% of waking hours);7 satisfactory haematological, 
renal, and hepatic function; and completion of baseline 
HRQoL questionnaires—European Organisation for 
Research and Treatment of Cancer (EORTC) QLQ-C30 
(version 3.0) and EORTC QLQ-STO22.8–10 Eligible patients 
had baseline haemoglobin greater than 100 g/L for study 
entry. Important exclusion criteria were previous 
chemotherapy with a taxane, grade 2–4 peripheral 
neuropathy, previous malignancy, and cerebral or 
leptomeningeal metastases. All participants provided 
written informed consent. Central randomi sation, data 
storage, and analysis were done by the Warwick Clinical 
Trials Unit (Coventry, UK). Trial coordination and 
pharmacovigilance was done by the Cambridge Cancer 
Trials Unit—Cancer Theme (Cambridge, UK). We 
obtained Multicentre Research Ethics Committee 
(MREC) approval from the UK National Research Ethics 
Service Committee South West-Exeter MREC (Bristol, 
UK). All aspects of the study were done in accordance 
with the Declaration of Helsinki including all of its 
relevant amendments, the guidelines for Good Clinical 
Practice of the International Conference on 
Harmonization, and all relevant UK and European laws 
and directives. An independent data monitoring and 
ethics committee monitored recruitment, safety, and 
outcome.
Randomisation and masking
This was an open-label study. We randomly allocated 
patients in a 1:1 ratio to either docetaxel plus active 
symptom control (docetaxel group) or active symptom 
control alone using a central computerised minimisation 
procedure generated at the Warwick Clinical Trials Unit. 
Trial allocations were stratifi ed by disease status (locally 
advanced vs metastatic disease), disease site (oesophagus 
vs oesophagogastric junction vs gastric), duration of 
response to previous chemotherapy (no response vs 
response duration <3 months vs response duration 
3–6 months), and performance status (0–1 vs 2). To 
conceal the sequence the investigator or research nurse, 
who recruited the patients, contacted the Warwick 
Clinical Trials Unit for each participant’s random 
allocation sequence. Because this was an open-label 
study, participants, investigators, and trials staff  were 
aware of treatment allocations.
Treatment
Active symptom control was off ered to all patients 
participating in the trial, and was delivered according to 
local pathways within each participating hospital and 
included community and hospice care. Docetaxel was 
given at a dose of 75 mg/m² of body-surface area by 
intravenous infusion over 1 h every 3 weeks for up to six 
cycles, which was the standard dose and schedule in the 
UK at the time of the study. We gave patients 
dexamethasone 8 mg orally, two times a day for three doses 
before each administration of docetaxel—ie, 
dexamethasone treatment starting 1 day before docetaxel 
administration (morning and evening) and about 1 h 
before docetaxel administration. We stipulated in the 
protocol that steroids were also given after treatment (ie, 
8 mg orally, two times a day for three doses), but local 
protocols were accepted. Hypersensitivity reactions were 
managed with supportive drugs as defi ned in the protocol. 
Dose modifi cation for haematological toxicity was based 
on a blood test before each cycle of chemotherapy. If the 
absolute neutrophil count (ANC) was greater than 
1·5 × 10⁹ cells per L or platelet count was above 100 × 10⁹ per 
L then treatment was continued at full dose. If a patients’ 
ANC was below 1·5 × 10⁹ cells per L treatment was delayed 
until recovery. If ANC recovered to greater than 
1·5 × 10⁹ cells per L within 14 days then treatment was 
restarted. Subsequent treatments were given at full dose 
unless there was lengthy grade 4 neutropenia (ANC less 
than 0·5 × 10⁹ cells per L for more than 7 days) or febrile 
neutropenia, in which case the dose of docetaxel was 
reduced to 55 mg/m² of body-surface area for subsequent 
cycles. If neutropenia persisted for more than 14 days no 
further docetaxel was given. If a patients’ platelet count 
was below 100 × 10⁹ per L treatment was delayed until 
recovery. If the platelet count recovered to greater than 
100 × 10⁹ per L within 14 days then treatment was restarted. 
Subsequent treatments were given at full dose unless the 
platelet count had fallen to less than 50 × 10⁹ per L, in which 
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case the dose of docetaxel was reduced to 55 mg/m² of 
body-surface area for subsequent cycles. If thrombo-
cytopenia persisted for more than 14 days no further 
docetaxel was administered. In the event of hepatic toxicity, 
defi ned as bilirubin greater than upper limit of normal, 
alanine aminotransferase or aspartate aminotransferase 
greater than 1·5 times the upper limit of normal, alkaline 
phosphatase greater than 2·5 times the upper limit of 
normal in the absence of liver metastases, or alkaline 
phosphatase greater than 5 times the upper limit of normal 
in the presence of liver metastases, then treatment was 
delayed until recovery and the dose of docetaxel was 
reduced to 55 mg/m² of body-surface area for subsequent 
cycles. Non-haematological toxicity was managed as 
follows: for cutaneous toxicity of grade 2 or greater, 
docetaxel was stopped until recovery to baseline. For grade 
2 toxicity subsequent treatments were given at full dose, 
whereas in the event of grade 3 or 4 toxicity, the dose of 
docetaxel was reduced to 55 mg/m² of body-surface area 
for subsequent cycles. Treatment was permanently 
discontinued if patients developed grade 3–4 peripheral 
neuropathy. For all other grade 3–4 non-haematological 
toxicities, treatment was interrupted until resolution and 
the dose of docetaxel was reduced to 55 mg/m² of body-
surface area for subsequent cycles.
Docetaxel was discontinued on completion of six 
cycles, delay of treatment for more than 21 days, disease 
progression, unacceptable toxicity, or patient request.
We reviewed patients on active symptom control alone 
every 3 weeks for the 18-week treatment period. Patients 
receiving docetaxel were reviewed before each cycle. In 
both trial groups, we assessed toxicity using the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events (version 3.0). At baseline and at each 
study visit a patient’s status was assessed by medical 
history, physical examination including performance 
status and weight, full blood count, and biochemical 
serum analysis. HRQoL questionnaires were handed out 
at weeks 3, 6, 9, 12, 18, and 24 on arrival at clinic visits for 
patients to complete themselves. We did CT scans of 
patients’ thorax and abdomen at baseline and after cycles 
three and six for patients receiving docetaxel. We 
measured and interpreted tumour according to RECIST 
(version 1.0) guidelines.11
On completion of docetaxel or after 18 weeks, patients 
were followed up every 6 weeks for up to 1 year. After 
1 year, patients were reviewed every 3 months until death.
Statistical analysis
The primary endpoint was overall survival. We needed a 
sample size of 320 patients to detect a median overall 
survival gain from 4 months to 6 months, assuming 
patients were recruited over a 2 year period and were 
followed up for a minimum of 6 months, with 90% 
power and two-sided alpha of 0·05. While the study was 
underway, a randomised trial was published that 
suggested a survival advantage for chemotherapy and a 
poorer overall survival for patients given active symptom 
control than we had assumed.12 We recalculated the 
sample size on the recommendation of the fi rst 
independent data monitoring and ethics committee in 
June, 2010, on the basis of poorer recruitment than 
expected and assuming a lower overall survival in the 
control group. A revised minimum total of 164 patients 
was therefore needed to detect a hazard ratio of 0·64, 
assuming 3·5 years recruitment, a two-sided alpha of 
0·05, and 80% power, but was suffi  cient to accommodate 
a range of potential outcomes (appendix).13
Secondary endpoints were best response to docetaxel, 
time to documented disease progression (for the 
docetaxel group), toxicity, and HRQoL. Important 
HRQoL endpoints identifi ed before we started the study 
were physical and social function and fatigue (QLQ-C30) 
and eating restrictions and dysphagia (QLQ-STO22).
We did all analyses on an intention-to-treat basis. 
We calculated overall survival from date of randomisation 
until date of death, censoring at the last known date 
alive. We calculated time to documented disease 
progression within 24 weeks from date of randomisation 
until date of progression, or death from disease without 
recorded progression if within 24 weeks. We constructed 
survival curves using the Kaplan-Meier method.14 We 
84 allocated to docetaxel active symptom control
 77 received allocated intervention
 7 did not receive allocated intervention
  3 died  
  1 refused treatment 
  1 withdrew
  1 delay >21 days
  1 patient admitted for another disorder
84 allocated to active symptom control
 78 received allocated intervention
 6 did not receive allocated intervention
  4 withdrew
  1 entered another trial
  1 had progressive disease
58 discontinued intervention
 26 progressive disease
 20 unacceptable toxicity
 7 died
 4 delay >21 days
 1 poor performance status
48 discontinued intervention
 32 died
 6 entered phase I trial
 4 patient decision (wanted chemotherapy)
  2 followed up at different hospital
 2 declined further assessments
 1 progressive disease
 1 withdrew
84 analysed for primary survival outcome
69 health-related quality of life
81 adverse events
56 response assessment
84 time to progression
84 analysed for primary survival outcome
57 health-related quality of life
74 adverse events
356 assessed for eligibility
188 excluded
 77 did not meet inclusion criteria
 71 declined to participate
 40 other reasons
168 randomised
Enrolment
Allocation
Outcome
Analysis
Figure 1: Trial profi le
See Online for appendix
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compared survival diff erences using a Cox proportional 
hazard model and calculated hazard ratios with 
95% CIs.15 We did a planned multivariate Cox-regression 
analysis for overall survival to adjust the treatment eff ect 
for the stratifi cation variables. We calculated hazard 
ratios for prognostic subgroups and constructed a 
hazard ratio plot.16
The delivered dose intensity for docetaxel was calculated 
as the ratio of actual dose received per week to the expected 
dose averaged over the number of cycles administered.
We analysed HRQoL data with a standardised area 
under the curve analysis and compared them using 
Wilcoxon rank sum tests.17 We handled missing 
questionnaire data by calculating the scale score if at least 
half of items were answered.18 We did sensitivity analyses 
adjusting for dropouts due to death using a quality-
adjusted survival analysis for the global HRQoL score.19
Reported p values are two sided and are considered 
statistically signifi cant at a value of less than 0·05. We 
used SAS (version 9.2) for all statistical analyses.
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN 13366390.
Role of the funding source
Neither the funders or sponsors of the trial participated 
in study design, in data accrual or analysis, or in the 
preparation of this paper. Access to the raw data was 
available to the statisticians (AM, JAD). The cor-
responding author had full access to all of the data and 
the fi nal responsibility to submit for publication.
Results
Between April 21, 2008, and April 26, 2012, we recruited 
168 patients (appendix), allocating 84 patients to each 
trial group (fi gure 1). Baseline characteristics were much 
the same between treatment groups (table 1; appendix). 
After randomisation, eight patients (four in each group) 
were deemed ineligible because they did not have 
documented disease progression within 6 months of 
previous chemotherapy (n=3) or unsatisfactory blood 
results (n=5). These patients all went on to receive the 
allocated treatment and were included in the analyses on 
an intention-to-treat basis.
255 treatment cycles were administered to the 
84 patients in the docetaxel group, with a median of three 
treatment cycles (IQR 1–5) per patient. In the docetaxel 
group, 19 (23%) of these 84 patients completed all six 
cycles of treatment, 17 (20%) received only one cycle, and 
seven (8%) had no docetaxel. Of the 65 patients who did 
not complete all six cycles, the three main reasons for 
early discontinuation of treatment were progressive 
disease in 26 (40%) patients, unacceptable toxicity in 
20 (31%) patients, and death in ten (15%) patients. 
Treatment delays were infrequent (occurring in 29 [11%] 
of 255 cycles) and were mainly due to toxicity (in ten 
[34%] cycles), administrative decisions (in eight [28%]), 
clinical decision (in six [21%]), or patient request (in three 
[10%]). The treatment dose was reduced in 23 (27%) 
patients for a total of 57 (22%) cycles. The overall median 
course dose intensity was 46% (IQR 19–74).
In the active symptom control group, 30 (36%) of 
84 patients completed at least 18 weeks of follow-up. The 
main reason for early discontinuation of follow-up was 
death (in 32 [59%] patients).
Docetaxel 
(n=84)
Active symptom 
control (n=84)
Sex
Male 69 (82%) 67 (80%)
Female 15 (18%) 17 (20%)
Age in years 65 (28–84) 66 (36–84)
Individuals older than 70 years 23 (27%) 16 (19%)
Eastern Cooperative Oncology Group performance status
0 24 (28%) 22 (26%)
1 46 (55%) 50 (60%)
2 14 (17%) 12 (14%)
Disease status
Locally advanced 11 (13%) 10 (12%)
Metastatic disease 73 (87%) 74 (88%)
Site of primary disease
Oesophagus 18 (22%) 15 (18%)
Oesophagogastric junction 27 (32%) 32 (38%)
Stomach 39 (46%) 37 (44%)
Time between end of previous chemotherapy and documented disease 
progression
During treatment 36 (43%) 36 (43%)
Within 3 months 27 (32%) 22 (26%)
3–6 months 21 (25%) 26* (31%)
Data are n (%) or median (range). *Three patients were subsequently shown to 
have longer than 6 months between end of previous chemotherapy and 
documented disease progression. 
Table 1: Baseline characteristics
Number at risk
Docetaxel 84 69 53 33 25 17 10 8 5 4 
Active symptom 84 70 38 19 13 9 6 2 1 1
control  
100
O
ve
ra
ll 
su
rv
iv
al
 (%
)
75
50
25
0
0 62 4 8 10 1612 14 18
Time from randomisation (months)
Docetaxel
Active symptom control
Hazard ratio=0·67 (95% CI 0·49–0·92); p=0·01
Figure 2: Kaplan-Meier plot of overall survival
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16 patients in the active symptom control group went 
on to have further systemic cancer treatment: 11 entered 
early phase clinical studies and fi ve had conventional 
chemotherapy. Seven patients in the docetaxel group 
went on to have further systemic cancer treatment: three 
entered early phase clinical trials and four received 
conventional chemotherapy.
At the time of the planned fi nal analysis, 6 months after 
we allocated the fi nal patient to treatment, 161 (96%) 
patients had died (80 patients [95%] in the docetaxel 
group and 81 [96%] in the active symptom control group). 
Median follow-up was 12 months (IQR 10–21); one 
patient in the control group was lost to follow-up after 
18 days. Median overall survival for patients allocated to 
docetaxel was 5·2 months (95% CI 4·1–5·9) compared 
with 3·6 months (3·3–4·4) for patients in the control 
group (hazard ratio 0·67, 95% CI 0·49–0·92, p=0·01; 
fi gure 2). Overall survival in the docetaxel group was 82% 
(95% CI 72–89) at 2 months and 39% (29–50) at 6 months, 
and in the control group was 84% (75–91) at 2 months 
and 23% (15–34) at 6 months. We estimated the number 
of patients needed to treat at 6 months to be seven 
(95% CI 3·9–34·8)—ie, seven patients would be needed 
to be treated with docetaxel to lead to one extra survivor 
at 6 months.
A multivariate Cox proportional hazard model showed 
that performance status (p=0·001) and disease status 
(locally advanced better than metastatic disease, hazard 
ratio 2·07, 95% CI 1·23–3·50; p=0·006) were predictors 
of overall survival (appendix). Patients with a per-
formance status of 0 had better overall survival than 
those with a performance status of 1 (hazard ratio 2·00, 
95% CI 1·35–2·96) or two (2·16, 1·27–3·66). Disease site 
(p=0·58) and time of progression (p=0·58) were not 
statistically signifi cant predictors of overall survival. The 
treatment eff ect remained statistically signifi cant in the 
multivariate analysis after adjustment for stratifi cation 
variables (p=0·03).
We detected a benefi t of docetaxel treatment after 
stratifying by performance status, disease status, site of 
disease, and time between end of previous chemotherapy 
and documented disease progression (fi gure 3). We saw 
Events/patients
Docetaxel ASC
Docetaxel events
(O–E) Var
Hazard ratio (95% CI)
0·0 0·5 1·0 1·5 2·0
ECOG PS
0
1
2
Stratified
Heterogeneity between groups χ22  =1·7, p=0·43
Disease status
Locally advanced
Metastatic disease
Stratified
Interaction between groups  χ21  =0·0, p=0·88
Disease site
Oesophagus
Oesophagogastric junction
Stomach
Stratified
Heterogeneity between groups χ22  =0·5, p=0·77
Progression
During treatment
Within 3 months
3–6 months
Stratified
Heterogeneity between groups χ22  =5·3, p=0·07
Unstratified
 
 22/24 (91·7%) 
 45/46 (97·8%) 
 13/14 (92·9%) 
 80/84 (95·2%) 
 
 9/11 (81·8%) 
 71/73 (97·3%) 
 80/84 (95·2%) 
 
 17/17 (100%) 
 26/28 (92·9%) 
 37/39 (94·9%) 
 80/84 (95·2%) 
 
 36/36 (100%) 
 26/27 (96·3%) 
 18/21 (85·7%) 
 80/84 (95·2%) 
 
 80/84 (95·2%)
 
 19/22 (86·4%)
 50/50 (100%)
 12/12 (100%)
 81/84 (96·4%)
 
 9/11 (81·8%)
 72/73 (98·6%)
 81/84 (96·4%)
 
 15/15 (100%)
 30/32 (93·8%)
 36/37 (97·3%)
 81/84 (96·4%)
 34/36 (94·4%)
 21/22 (95·5%)
 26/26 (100%)
 81/84 (96·4%)
 81/84 (96·4%)
 –6·0
  –5·0
 –1·2
 –12·2
 –1·5
 –14·3
 –15·8
 –2·2
 –7·3
 –5·5
 –15·0
 –3·1
 –2·6
 –9·6
 –15·3
 –15·3
 8·1
 22·7
 5·9
 36·7
 4·1
 33·1
 37·2
 7·0
 12·7
 17·1
 36·8
 16·9
 10·7
 8·7
 36·4
 37·6
0·48 (0·24–0·95)
0·80 (0·53–1·21)
0·81 (0·36–1·82)
0·72 (0·52–0·99)
(p=0·04)
0·70 (0·27–1·84)
0·65 (0·46–0·91)
0·65 (0·48–0·90)
(p=0·01)
0·73 (0·35–1·52)
0·56 (0·32–0·98)
0·73 (0·45–1·17)
0·67 (0·48–0·92)
(p=0·01)
0·83 (0·52–1·34)
0·79 (0·43–1·43)
0·33 (0·17–0·65)
0·66 (0·47–0·91)
(p=0·01)
0·67 (0·48–0·92)
(p=0·01)
Docetaxel better Active symptom control better
Figure 3: Hazard ratio plot of the treatment eff ect by prognostic factors for overall survival
ECOG PS=Eastern Cooperative Oncology Group performance status.
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no statistically signifi cant heterogeneity between the 
subgroups of each of these factors (fi gure 3).
For the 56 patients in the docetaxel group assessable 
for response, best response to treatment was partial 
response in four (7%) patients, stable disease in 26 (46%) 
patients, and progressive disease in 24 (43%) patients. 
Response data were unavailable in two (4%) patients. 
Median time to progression was 12·2 weeks (95% CI 
9·1–18·6) for patients in the docetaxel group. 
Progression-free survival at 6 weeks was 88% (79–93) and 
at 24 weeks was 29% (19–38).
Ten deaths (seven in the docetaxel group and three in 
the active supportive care group) occurred within 30 days 
of randomisation. Five of the seven patients allocated to 
docetaxel died before receiving treatment and two deaths 
were after the fi rst docetaxel cycle. A further three 
patients died within 30 days of receiving docetaxel. 
Hence, fi ve (6%) deaths were within 30 days of receiving 
any docetaxel, but none was attributed to chemotherapy.
More patients in the docetaxel group had one or more 
grade 4 toxicity compared with those in the control group 
(17 [21%] patients vs three [4%] patients). Neutropenia, 
infections, and febrile neutropenia were more common 
in the docetaxel group versus the control group (table 2). 
Haemorrhage and pain were more common in the 
control group than in the docetaxel group (table 2).
560 (69%) of 812 HRQoL forms were returned: 
318 (72%) of 442 in the docetaxel group and 242 (65%) of 
370 in the active supportive care group (appendix). The 
main reasons for non-completion of the absent 
242 on-study HRQoL forms were: administration error 
(75 [31%] of 242 patients), patient  unwell (50 [21%] of 
242 patients), or patient refused or did not attend 
(48 [20%] of 242 patients). By 24 weeks, 118 (70%) patients 
had died or were off  study and no longer participating in 
HRQoL (51 [61%] patients in the docetaxel group, and 
67 [80%] patients in the active supportive care group).
Baseline QLQ-C30 and QLQ-STO22 scores were 
similar in both groups. Benefi ts for docetaxel were seen 
in all pre-specifi ed important domains, of which 
dysphagia was statistically signifi cant (p=0·02), and for 
several exploratory domains (fi gure 4).
Patients in the docetaxel group reported less general 
pain (p=0·0008), abdominal pain (p=0·01), nausea and 
vomiting (p=0·02), and constipation (p=0·02) than those 
in the control group, but similar global HRQoL (p=0·53; 
appendix). Findings from our sensitivity analysis 
adjusting for dropouts showed that the mean overall 
quality-adjusted life weeks over the restricted 24-week 
reporting period was 12·1 weeks (SD 0·84) for the 
docetaxel group and 9·3 weeks (0·73) for the control 
group—docetaxel treatment, therefore, provided on 
average an extra 2·8 adjusted life weeks compared with 
active symptom control.
Discussion
Our fi ndings suggest that, compared with active 
symptom control, docetaxel improves survival with no 
adverse eff ects on global HRQoL and improvement in 
some HRQoL symptom domains in patients with 
Docetaxel (n=81) Active symptom control (n=74)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia without fever 1 (1%) 0 4 (5%) 8 (10%) 0 0 0 0
Anaemia 8 (10%) 10 (12%) 3 (4%) 2 (2%) 7 (9%) 6 (8%) 3 (4%) 1 (1%)
Other blood or bone marrow 7 (9%) 0 2 (2%) 0 3 (4%) 1 (1%) 1 (1%) 1 (1%)
Infection without neutropenia 1 (1%) 8 (10%) 9 (11%) 3 (4%) 5 (7%) 8 (11%) 2 (3%) 0
Febrile neutropenia 0 0 5 (6%) 1 (1%) 0 0 0 0
Constitutional symptoms 16 (20%) 26 (32%) 13 (16%) 0 11 (15%) 14 (19%) 10 (14%) 0
Gastrointestinal 20 (25%) 28 (35%) 21 (26%) 0 18 (24%) 24 (32%) 18 (24%) 0
Haemorrhage or bleeding 4 (5%) 3 (4%) 0 1 (1%) 3 (4%) 1 (1%) 4 (5%) 1 (1%)
Metabolic or laboratory 7 (9%) 7 (9%) 5 (6%) 0 6 (8%) 5 (7%) 3 (4%) 0
Musculoskeletal or soft tissue 1 (1%) 3 (4%) 4 (5%) 0 2 (3%) 0 5 (7%) 0
Neurology 11 (14%) 10 (12%) 3 (4%) 0 10 (14%) 1 (1%) 3 (4%) 0
Pain 17 (21%) 19 (23%) 7 (9%) 2 (2%) 14 (19%) 26 (35%) 15 (20%) 0
Pulmonary or upper respiratory 12 (15%) 6 (7%) 3 (4%) 2 (2%) 8 (11%) 6 (8%) 5 (7%) 0
Allergy or immunological 2 (2%) 3 (4%) 1 (1%) 1 (1%) 1 (1%) 0 0 0
Lymphatic 3 (4%) 3 (4%) 0 0 1 (1%) 1 (1%) 1 (1%) 0
Visual 2 (2%) 1 (1%) 1 (1%) 0 1 (1%) 0 0 0
Renal or genitourinary 1 (1%) 0 1 (1%) 0 0 0 0 0
Vascular 1 (%) 0 1 (1%) 0 0 0 0 0
Dermatological 22 (27%) 12 (15%) 0 0 12 (16%) 0 0 0
Data are n (%) for the worst grade experienced for each adverse event listed.
Table 2: Adverse events
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oesophagogastric adenocarcinoma whose disease has 
progressed after fi rst-line treatment with platinum-based 
and fl uoro pyrimidine-based chemotherapy.
Previously there was no consensus recommendation 
for second-line chemotherapy in oesophagogastric 
adenocarcinoma.20  However, a comprehensive evidence 
base is now emerging (panel).20 Findings from a German 
trial of 40 patients with advanced oesophagogastric 
carcinoma randomly allocated to either irinotecan or best 
supportive care was stopped early due to poor 
recruitment, but patients treated with irinotecan had a 
median overall survival of 4·0 months compared with 
2·4 months for those given best supportive care (hazard 
ratio 0·48, 95% CI 0·25–0·92).12 In another trial, 
treatment with physician’s choice of either irinotecan or 
docetaxel in 133 patients with advanced gastric cancer 
resulted in a median overall survival of 5·3 months 
compared with 3·8 months for 69 patients treated with 
best supportive care, with equivalent effi  cacy of the two 
drugs.3 The strength of the fi ndings of both trials, 
however, are limited by the absence of robust HRQoL 
data, although the German group did note improvements 
in symptoms with chemotherapy.
Biological agents are also under assessment in this 
setting. The fi ndings of a phase 3 trial of the mTOR 
inhibitor everolimus showed no benefi t compared with 
placebo (overall survival 5·4 vs 4·3 months; 
p=0·12).23 Targeting of angiogenesis might be a more 
productive avenue of investigation. Findings from a 
study of 355 patients with gastrooesophageal 
adenocarcinoma treated in the second-line setting with 
either placebo or with ramucirumab, an inhibitor of 
VEGFR-2, showed a survival advantage for ramucirumab 
with median overall survival of 5·2 months versus 
3·8 months (hazard ratio 0·78 [95% CI 0·60–1·00]; 
p=0·047).24 Another group have reported the results of a 
randomised phase 2 trial comparing apatinib (YN968D1; 
another VEGFR-2 inhibitor) 850 mg given either as a 
single or divided dose with placebo.25 Patients treated 
with either schedule of apatinib had better overall 
survival (4·83 months and 4·27 months, respectively, vs 
2·5 months for placebo; p<0·001 and p=0·0017, 
respectively).25
We believe that our fi ndings add several important 
factors to the present evidence base. The largest 
previously published trial of chemotherapy was done in 
an Asian population with gastric cancer only.3 Therefore, 
the fi ndings of that trial are not ideally suited to guide 
treat ment outside of Asia because evidence exists that 
tumour biology diff ers between people of Asian origin 
and those of white patients.2,26 We know of no other trial 
that included patients with oesophageal adenocarcinoma 
in addition to those with oesophagogastric junction and 
gastric adenocarcinoma. Our fi ndings showed improve-
ment in all sites, although the trial was not powered to 
show statistical signifi cance for each site individually. 
The median age of 65 years in our study was more 
representative of the population seen in clinical practice 
than in other studies in which the median age was less 
than 60 years.3,12 We also included patients with an ECOG 
performance status of 0–2. The only other trial we know 
of that included any patients with a performance status 
of 2 had only four such patients in the treatment group.12
The slight survival benefi t achieved by administration of 
toxic chemotherapy necessitates careful assessment of 
HRQoL, toxicity, and disease-specifi c symptoms. HRQoL 
data are important to inform clinical decision making, and 
to provide patients with information about likely eff ects of 
treatment on functional aspects of health and 
symptoms.27 Studies that have measured HRQoL in gastric 
cancer often have incomplete datasets or poor reporting, 
which limits their application. We know of no other study 
to report comprehensive HRQoL assessment in second-
line treatment of advanced oesophagogastric cancer 
according to the CONSORT PRO guidelines.28 Our data 
show that the survival advantage associated with docetaxel 
treatment also has HRQoL benefi ts; in particular, pain 
scores are improved with the intervention. This fi nding is 
in keeping with other research showing the predictive 
value of self-reported pain and survival in oesophagogastric 
cancer.29 Unfortunately, however, the health of this 
population of patients deteriorates rapidly, meaning that 
questionnaire return is often problematic—our study was 
no exception, with only 57% of questionnaires returned in 
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Figure 4: Health-related quality of life (HRQL) outcomes.
Positive values in function scale and negative values for the symptom scale denote benefi t from docetaxel 
compared with active symptom control.
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the active symptom control group at 6 weeks. Such low 
questionnaire return is a limitation of the study, and might 
in part explain why dysphagia was the only prespecifi ed 
endpoint to show a benefi t in favour of docetaxel. 
Undertaking home visits might be the only way to improve 
response to HRQoL surveys in such trials.30
We did not measure time to progression in the active 
symptom control group. In a population with known 
progressive disease at study entry the value of measuring 
time to progression in a population not receiving cancer 
treatment is questionable, and we felt that it was not 
appropriate to subject these patients to additional 
unnecessary investigations. The study was planned on 
the basis that the endpoints to drive change in practice 
would be overall survival and HRQoL. Patients in both 
arms of the trial were allowed to receive other treatments 
after study completion, and a greater number did so in 
the control group (16 patients) than the docetaxel group 
(seven patients). If anything, this disparity might be 
expected to improve outcomes in the control group, and 
reduce the recorded benefi t of docetaxel.
There are areas of possible bias in this trial, principally 
the open-label design without placebo control (which was 
felt to be unavoidable given the very obvious toxicities of 
docetaxel such as alopecia and the ethical diffi  culty 
associated with a placebo infusion). The sex ratio in the 
trial (81% male) is higher than would be expected for the 
UK oesophagogastric cancer population, generally, in 
which where the male-to-female ratio is about 65 men to 
35 women. The reasons for this high proportion of men 
are not clear.
Patients in the docetaxel group received steroids with 
each infusion, which has some potential to bias the 
HRQoL scores, as does the rate of non-completion of 
questionnaires. Additionally, although active symptom 
control was provided for all patients in the trial, and 
included access to community palliative care and hospice 
services, we could not standardise the type of active 
supportive care fully, which is another potential source of 
bias. This possible bias was mitigated by the fact that 
patients continued to have regular review at the treating 
centre, with only one patient in the control group lost to 
follow-up.
The evidence for improvement in HRQoL with 
docetaxel, particularly reduced pain, and the survival 
gain are both consistent with a benefi cial eff ect from 
chemotherapy. Our fi ndings show that the toxicity of 
chemotherapy is more than compensated for by gains in 
symptom control, with no deterioration in global 
function. 
Future clinical trials are needed to further improve 
outcome in this globally common cancer. Our fi ndings 
have shown that it is possible to gather and report 
informative HRQoL data in this poor-prognosis group. 
Future trials, which should include HRQoL outcome 
measures, should focus on optimising chemotherapy 
and the addition of relevant biological agents.
On the basis of our fi ndings, we believe that 
chemotherapy should be off ered to fi t patients for the 
second-line treatment of oesophagogastric adeno-
carcinoma, and that treatment with docetaxel can 
improve some aspects of quality of life for patients. 
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Panel: Research in context
Systematic review
We identifi ed a systematic review of second-line chemotherapy versus supportive cancer 
treatment in advanced gastric cancers21 that searched the Cochrane Central Register of 
Controlled Trials (CENTRAL, Issue 1, 2013), Medline (1950 to March week 4, 2013), and 
EMBASE (1980 to 2013, week 13) for articles that included the following terms “gastric or 
gastroesophageal or gastroesophagus or esophagogastric or stomach”, “cancer or 
neoplasm or carcinoma or malignant or malignancy”, “second line or salvage or supportive 
care”, “chemotherapy or chemotherapeutic or antineoplastic agent”, and “randomized or 
randomised, controlled trial or randomised”, and searched the reference lists of relevant 
articles and reviews and used the related articles feature in PubMed to identify additional 
articles. The investigators also searched all abstracts from American Society of Clinical 
Oncology conferences held between 2004 and 2013 and sought expert opinion to identify 
relevant but unpublished studies. These authors assessed all potentially eligible studies 
identifi ed by the above search strategy. Clinical trials that met the following criteria were 
included in the meta-analysis: trials comparing second-line or salvage treatment 
chemotherapy with best supportive care, and prospective phase 3 randomised trials. The 
investigators21 did a meta-analysis of the three high-quality randomised trials identifi ed 
(including the initial report of our trial, presented at the American Society of Clinical 
Oncology annual meeting in Chicago, IL, USA, held on May 31 to  June 4, 2013), and 
reported a reduction in the risk of death with second-line chemotherapy with no 
diff erences in treatment eff ect between docetaxel and irinotecan. They also noted that our 
trial was the only one to address quality of life. The methodology for the systemic review 
was robust, although the meta-analysis was limited by the absence of patient-level data. 
However, the fi ndings are lent support by another trial that reported no diff erence 
between outcomes for patients treated with either paclitaxel or irinotecan22 and are the 
best available assessment of the evidence in this subject area.
Interpretation
The results of our trial and others provide level A evidence that second-line chemotherapy 
can provide both survival and quality-of-life benefi ts to selected patients who have 
progressed after fi rst-line treatment for oesophagogastric adenocarcinoma. Docetaxel, 
paclitaxel, and irinotecan have all shown activity and can be regarded as appropriate for use 
as second-line treatment, with this study providing new evidence of quality-of-life benefi t 
with docetaxel. All fi t patients who progress after fi rst-line treatment should therefore be 
considered for second-line chemotherapy. In practice, patients who have received a taxane 
as part of their primary treatment are likely to be treated with irinotecan, whereas those who 
have not could be considered for either second-line irinotecan or taxane therapy. The role of 
biological agents such as ramucirumab and apatinib will depend on the results of future trials 
and regulatory approval, but addition of these agents could prove to add benefi t to that 
already seen with chemotherapy.
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